PSA Prostate Cancer Screening Does More Harm Than Good, USPSTF Concludes
This article was originally published in The Gray Sheet
Executive Summary
The final recommendations are a major shift in policy for the commonly performed blood test, and one certain to face ongoing controversy.
You may also be interested in...
CMS Issues List Of Potential National Coverage Determination Topics
Most of the 33 items or services in the list have implications for manufacturers of medical devices, combination products or diagnostics.
Capitol Hill In Brief
Prostate Cancer Detection Research and Education Act introduced in House and Senate. Safe Doses Act, to increase fines for medical product thefts and counterfeiting, passes House. More Capitol Hill briefs.
New Products In Brief
Recent market launches and clearances include Glaukos’ iStent for glaucoma, Beckman Coulter’s Prostate Health Index blood test for prostate cancer and Siemens’ Sysmex CA-600 Systems for lab hemostasis testing.